Menu Menu

News

Topics
Featured
COVID-19 Research Pipeline

190,093

Registered/ Published

4,540

Registered

753

Published

7,055

Registered
As at 02 December 2022
FILTERED BY > Nirmatrelvir plus ritonavir (Paxlovid) Clear filter

Communique #72

27 September, 2022
Click for the latest Taskforce news: 
Communique

Communique #69

2 August, 2022
Click for the latest Taskforce news: 
Communique

Vaccine language changes in paediatric and pregnancy recommendations

2 August, 2022
Further to recent changes to vaccine status across the recommendations for adults with mild COVID-19, the following paediatric and pregnancy recommendations have now been updated: Nirmatrelvir plus ritonavir...
News

Communique #68

22 July, 2022
Click for the latest Taskforce news: 
Communique

Update to recommendations for adults with mild COVID-19

21 July, 2022
To reflect changing language from ATAGI and to remove confusion among clinicians about what ‘up-to-date’ with vaccination means, the Taskforce has replaced this terminology across all relevant adult...
News

I have mild COVID – should I take the antiviral Paxlovid?

30 May, 2022
How effective is Paxlovid in treating mild COVID-19? Taskforce Director, Tari Turner, together with Primary Chronic Care Co-Chairs Nicole Allard and Mark Morgan and Disease-Modifying Treatments & Chemoprophylaxis...
News

Communique #65

9 May, 2022
Click for the latest Taskforce news:
Communique

I’ve tested positive for COVID-19? What treatments are available?

9 March, 2022
  With several new drug treatments for people with mild COVID-19 now available, it can be tricky to know what your options are should you test positive to...
Explainer

Communique #59

7 March, 2022
Click for the latest Taskforce news:
Communique

Communique #58

18 February, 2022
Click for the latest Taskforce news:
Communique

Communique #57

3 February, 2022
Click for the latest Taskforce news:
Communique

Communique #56

31 January, 2022
Click for the latest Taskforce news:
Communique